Last reviewed · How we verify
Avelumab and Pepinemab
At a glance
| Generic name | Avelumab and Pepinemab |
|---|---|
| Sponsor | Vaccinex Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avelumab and Pepinemab CI brief — competitive landscape report
- Avelumab and Pepinemab updates RSS · CI watch RSS
- Vaccinex Inc. portfolio CI